Rethinking Trial Design for Rare Diseases

About this episode

The episode discusses the challenges and innovative approaches in trial design for rare diseases.

Rare disease drug development has a design problem. In this episode of The Emerging Biotech Leader, hosts Kim Kushner and Ramin Farhood speak with Marshall Summar, CEO and founder of Uncommon Cures, who has run more than 200 rare disease trials across academic medicine and industry. His core argument: sponsors are still defaulting to trial models built for large, homogeneous populations, in diseases where the entire patient pool may number fewer than 150 people. "You need to pick a design that's appropriate for the size of the population you have and the outcomes you're looking at." - Marshall Summar The double-blind placebo-controlled trial has its place. That place is not a disease with 80 patients in the world. Better-fit designs exist: patient-as-own-control models, adaptive phases that allow course corrections before they become costly, natural history studies funded through patient organizations before a trial opens. Reducing patient burden, home drug delivery, remote consent, home nursing visits, is a data integrity decision as much as a patient experience one. Pediatric inclusion from the start produces stronger evidence and a cleaner access story than studying adults and…

People in this episode

Hosts: Kim Kushner, Ramin Farhood

Guest: Marshall Summar

Topics covered

• rare diseases
• trial design
• drug development
• patient engagement
• clinical trials

Keywords

• rare disease trials
• clinical trial design
• patient-as-own-control
• adaptive phases
• pediatric inclusion

Mentioned in this episode

Organizations: Uncommon Cures

More episodes of The Emerging Biotech Leader

• Designing Studies that Work in Complex Settings · May 22, 2026 · 19 min
• Driving Global Patient Access: Managed Access as a Strategic Lever · February 4, 2026 · 22 min
• Rare Disease Commercialization: Beyond Approval · January 14, 2026 · 32 min
• Clinical Operations as a Strategic Function · December 2, 2025 · 21 min
• How Clinical Operations Shapes Biotech Strategy · November 20, 2025 · 46 min
• 50 Episodes in: Lessons from The Emerging Biotech Leader · November 10, 2025 · 36 min